P159 - Urodynamic assessment of orthotopic neobladder reconstruction following radical cystectomy in bladder cancer

Publication date: November 2018Source: European Urology Supplements, Volume 17, Issue 14Author(s): N. Kostakopoulos, V. Argiropoulos, K. Tsirkas, K. Spiropoulos, L. Lazarou, I. Varkarakis, A. Skolarikos
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research

Related Links:

Analyst, 2019, Accepted Manuscript DOI: 10.1039/C9AN01911A, PaperFabian Placzek, Eliana Cordero, Simon Michael Kretschmer, Lara Wurster, Florian Knorr, Gerardo Gonzales-Cerdas, Mikael T. Erkkilae, Patrick Stein, Caglar Ataman, Gregers Hermann, Karin Mogensen, Thomas Hasselager, Peter E. Andersen, Hans Zappe, J ürgen Popp, Wolfgang Drexler, Rainer Leitgeb, Iwan W. Schie Non-muscle-invasive bladder cancer affects millions of people worldwide, resulting in significant discomfort to the patient and potential death. Today, cystoscopy is the gold standard for bladder cancer assessment, using white... The content of this RSS...
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
Condition:   Bladder Cancer Intervention:   Diagnostic Test: immediate urine cytology Sponsor:   Mansoura University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
PROSTATE cancer is the most common cancer in men in the UK and treatment outcomes depend greatly on how early it is caught. The warning signs associated with the disease are associated with the bladder and men who experience a certain issue in cold weather should not rule out the disease.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Conclusions: Easy-to-use eCRFs were developed and included in the electronic patient file system. This registration tool was implemented in 7 hospitals, 6 of which are still using it today. The register harvests important clinical data, while performing routine clinical practice. The data will be used to analyze real-life data of NMIBC patients, to challenge the existing guidelines, to create novel risk stratification tools, and to develop, monitor and validate quality parameters for NMIBC management.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We present a case of GCA in a patient who presented with jaw claudication and occlusal pain. A 78-year-old man visited our department with left-sided facial pain associated with mastication. He also reported spontaneous left-sided facial pain and diminished vision. Based on his age, his new-onset left-sided headache, and a high erythrocyte sedimentation rate, he was diagnosed with GCA with immediate initiation of prednisolone (PSL) therapy. His fever subsided the following day. A temporal artery biopsy (TAB) was performed 7 days after hospitalization and showed a false-negative result. His left-sided facial pain and headac...
Source: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology - Category: ENT & OMF Source Type: research
CicloMed LLC has expanded a clinical trial for an anti-cancer drug that could potentially transform the treatment of bladder cancer. Researchers at the University of Kansas Cancer Center and its Institute for Advancing Medical Innovation (IAMI) first discovered the treatment several years ago. Now, the drug is licensed out to CicloMed, a Kansas City-based biotechnology company formed by IAMI and Kansas City venture capital firm BioNovus Innovations LLC. Fosciclopirox is set to become the first…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
CicloMed LLC has expanded a clinical trial for an anti-cancer drug that potentially could transform the treatment of bladder cancer. Researchers at The University of Kansas Cancer Center and its Institute for Advancing Medical Innovation (IAMI) first discovered the treatment several years ago. Now, the drug is licensed to CicloMed, a Kansas City-based biotechnology company formed by IAMI and Kansas City venture capital firm Bio Novus Innovations LLC. Fosciclopirox is set to become the first KU Cancer…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
CONCLUSIONS: Overall, adherence to NMIBC guidelines was low in all treatment types (intravesical therapy, re-resection, or cystectomy for very high-risk patients), but this finding was similar to that in previous studies. Reasons were mainly related to the urologist's decision or to the patient condition (poor compliance or poor general health status). LEVEL OF EVIDENCE: 3. PMID: 31813714 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
CONCLUSION: Cancer risk in CRS patients is significant high than non-CRS patients, especially in head and neck, breast, lung, bladder, colorectal, liver, prostate, and skin cancers. Surgical interventions in CRS patients could not decrease cancer risk in CRS patients. PMID: 31814917 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
In this study, hnRNP-F was found to be upregulated in BC tissues and cells by western blotting. The knockdown of hnRNP-F could inhibit proliferation and delay cell cycle progression in EJ and UMUC-3 cells. Mechanistically, hnRNP-F was shown to bind to Targeting protein for Xenopus kinesin-like protein 2 (TPX2) by mass spectrometry and coimmunoprecipitation. Furthermore, Pearson correlation analysis showed that the expression of hnRNP-F was positively associated with that of TPX2 in BC tissues (P
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Urology & Nephrology